CSL Behring
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. Its line of therapies includes products for the treatment of bleeding disorders such as hemophilia and von Willebrand Disease; primary immune deficiencies (PIDD); hereditary angioedema; inherited respiratory disease; and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment, and to prevent hemolytic diseases in newborns.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name | Drug Name | Approved | Patent Expires | Indication |
|---|---|---|---|---|
| Afstyla | Lonoctocog alfa, Antihemophilic factor (recombinant), single chain | 2017-01-04 | ||
| Albuminar, albuminar, albuminar, albuminar | Albumin (human) | 2000-03-17 | — | |
| Alburx | Albumin (human) | 1976-07-23 | — | |
| Berinert | C1 esterase inhibitor (human) | 2009-10-09 | ||
| Carimune, carimune nf, panglobulin, sandoglobulin | Immune globulin intravenous (human) | 2000-07-27 | — | |
| Gammar i.v.,gammar-p | Immune globulin intravenous (human) | 2000-03-17 | — | |
| Haegarda | C1 esterase inhibitor subcutaneous (human) | 2017-06-22 | ||
| Hizentra | Human normal immunoglobulin (scig), Immune globulin subcutaneous (human), liquid | 2011-04-14 | — | |
| Humate-p | Antihemophilic factor, Von willebrand factor complex (human) | 2000-04-11 | — |
1
2
>
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Indication |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use